This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.

Our diverse portfolio helps us deliver on our commitment to Women's Health

20 September 2021

UK FemSeven® (estradiol +/- levonorgestrel) Supply Update: Sep 2021

FemSeven® 50 and 75 return to the UK Market

Theramex holds the marketing authorisation for FemSeven® 50, 75 and 100 (estradiol), FemSeven® Conti (estradiol/levonorgestrel) and FemSeven® Sequi (estradiol/levonorgestrel) in the UK and Europe since acquiring these products from Teva Pharmaceuticals Ltd on 1st February 2018.

Non-patient-safety related quality issues were brought to our attention resulting in the gradual withdrawal of the FemSeven® portfolio from the market. We have since worked diligently to fix these issues and we are in the process of completing all of the necessary quality testing to bring the entire portfolio back to market.

FemSeven® Conti returned to the UK market in January. It continues to be fully in stock with no supply issues anticipated.

We are now pleased to confirm that FemSeven® 50 and 75 are also available.

The next product to return to market will be FemSeven® 100, which is undergoing the final testing process and is anticipated to return to market by the end of 2021. This will be followed by FemSeven® Sequi, which is expected in Q1 2022.

CountryProduct NameDates of Availability
UKFemSeven® Conti (estradiol/ levonorgestrel)
FemSeven® Sequi (estradiol/ levonorgestrel)
FemSeven® 50 (estradiol)
FemSeven® 75 (estradiol)
FemSeven® 100 (estradiol)
Fully available®
Expected Q1-22®
Fully available ®
Fully available
Expected Q4-21

Further Information

Patients who have any questions with regards to their treatment options should speak to their general practitioner.

For pharmacists and healthcare professionals who wish to place orders for the FemSeven® Conti, please contact Alliance Healthcare via your usual channels.

27 September 2021

Theramex supports World Contraception Day as it continues to champion women’s rights to effective and reliable birth control

Read more

31 August 2021

Real-world evidence demonstrates significant difference in fracture risk reduction for osteoporosis patients using gastro-resistant risedronate (Actonel® GR*) when compared with those using alendronate IR oral bisphosphonate

Read more